Botulinum toxin type A in treating early-stage patients with small-angle acute acquired comitant esotropia  

作　　者：Run-Ting Ma Die-Wen-Jie Hu Lian-Hong Zhou Wen-Ping Li Yuan-Jin Li Bei-Xi Yi 

机构地区：[1]Department of Ophthalmology,Renmin Hospital of Wuhan University,Wuhan 430060,Hubei Province,China

出　　处：《International Journal of Ophthalmology(English edition)》2024年第6期1094-1101,共8页国际眼科杂志（英文版）

基　　金：Supported by Key Research and Development Program of Hubei Province(No.2022BCA044);the Central Guided Local Science and Technology Development(No.2019ZYYD058).

摘　　要：AIM:To investigate botulinum toxin A(BTXA)efficacy on small-angle(≤25Δ)acute acquired concomitant esotropia(AACE)in early-stage patients.METHODS:The electronic medical record data of AACE patients during March 2019 and June 2023 were collected in this retrospective and hospital-based cohort study.A total of 72 small-angle AACE patients received BTXA extraocular muscle injection.Patients were grouped by onset-to-treatment time(Group A:≤6mo,Group B:>6mo).Deviation of esotropia,eye alignment and stereopsis were analyzed at the period of pre/post-injection(1wk,1,3,and 6mo).Orthophoria rate at 6mo(horizontal deviation<10Δand binocular single vision)were considered as outcome index.RESULTS:There were no significant baseline differences(P>0.05)between two groups except onset-to-treatment time(2mo vs 11mo,P<0.001).Higher orthophoria rates were in Group A at last follow-up(94.74%vs 73.53%,P=0.013).Post-BTXA deviations of two groups at 1mo showed no difference(P>0.05);while in 3 and 6mo Group A was significantly smaller than group B(all P<0.001).No statistically significant differences were observed among all post-BTXA deviations of near and distance in Group A.In Group B,deviation at 3mo(near:2Δvs 0,P<0.001;distance:4Δvs 0,P<0.001)and 6mo(near:6Δvs 0,P<0.001;distance:6Δvs 0,P<0.001)was significant increased compared to deviation at 1wk after treatment.Group A showed better stereopsis recovery in last follow-up compared to Group B(80″vs 200″,P=0.002).Both groups obtained improved stereopsis after treatment(Group A:80″vs 300″,P<0.001;Group B:200″vs 300″,P=0.037).CONCLUSION:BTXA is effective for AACE with small deviation(≤25Δ)in early stage.Delayed treatment(>6mo)may reduce BTXA efficacy.Early BTXA intervention benefits long-term eye alignment and stereopsis recovery.

关 键 词：acute acquired comitant esotropia botulinum toxin type A STEREOPSIS 

分 类 号：R777.41[医药卫生—眼科]